The Scientist’s Financial Education: What You Don’t Know Can Cost You Your Company
Why financial literacy is not optional for life sciences founders and CEOs.
I have worked with brilliant Ph.D. scientists who understand their technology better than anyone else in the room, yet struggle to explain how that technology creates economic value.
They can describe the mechanism of action in exquisite detail, defend the clinical data, and articulate the unmet medical need.
But ask them about liquidation preferences, risk-adjusted valuation, dilution, or the cost of capital, and the conversation changes.
I have seen founders celebrate a successful financing without fully understanding what they gave up in ownership and rights to secure it.
Raising capital is not the same as creating value. And a great valuation does not necessarily mean a great deal.
That distinction is fundamental to Chapter 2 of my book, Dual Fluency.
Why Financial Literacy Matters
Scientists are trained to evaluate hypotheses, interpret data, and manage uncertainty.
Investors are trained to evaluate risk, allocate capital, and generate returns.
The challenge is that life sciences founders must operate in both worlds, often without formal financial training.
A founder who does not understand the financial implications of a term sheet may surrender more ownership or control than necessary.
A CEO who cannot evaluate risk-adjusted returns may allocate scarce capital to the wrong development milestone.
A leadership team focused exclusively on securing the next financing may overlook alternative capital sources or the longer-term consequences of the financing structure.
These are not accounting problems.
They are leadership decisions that determine who controls the company, who captures the value, and whether the science advances.
The Decisions Begin Before the Term Sheet
One misconception I frequently encounter is that financial sophistication becomes important when a company starts negotiating financing terms.
By then, many consequential decisions have already been made.
Which investors did you approach? How much capital did you seek? What milestones did you promise? What risks did you communicate? Did you understand how investors would value the next clinical inflection point?
Each decision influences your negotiating leverage.
And each can have consequences that persist long after the financing closes.
Financial literacy is not about becoming an investment banker.
It is about understanding enough to challenge assumptions, evaluate alternatives, and recognize when a seemingly attractive financial decision may compromise the company’s future.
What Every Scientist-Founder Should Understand
Three questions deserve particular attention.
1. Do you understand the true cost of your capital?
Equity, debt, royalty financing, and non-dilutive funding carry different economic obligations and strategic consequences. Capital is not interchangeable.
2. Do you understand how investors value uncertainty?
Scientific promise alone does not establish enterprise value. Investors evaluate probabilities, timelines, future capital requirements, and potential returns. Understanding that framework changes how you allocate resources.
3. Do you understand what you are giving away?
Headline valuation is only one element of a financing. Liquidation preferences, anti-dilution protections, governance rights, and option pool provisions can have profound consequences for ownership and control.
You do not need to negotiate every provision yourself. But you must understand what those provisions mean.
The Real Cost of Financial Illiteracy
In life sciences, capital is finite, development is expensive, and the margin for error is unforgiving.
A poorly structured financing can constrain future choices. A misunderstood term sheet can transfer economic value away from founders and existing shareholders. A poorly timed capital raise can weaken a company precisely when it should be strengthening its position.
And when those mistakes compromise the development of a promising therapy, the consequences extend beyond investors and management.
Scientific excellence may create the opportunity. Financial literacy helps preserve it.
That is why understanding the language of capital matters.
And why the scientist’s financial education is not optional.
This article introduces Chapter 2, “The Scientist’s Financial Education,” from my book, Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital.
I would welcome your perspective. What financial lesson do you wish you had learned earlier in your career as a founder, CEO, or life sciences executive?
David H. Crean, PhD
Author, Dual Fluency